A A Gheorghisan-Galateanu1,2, D Terzea2,3, A Valea4, M Carsote2. 1. "Carol Davila" University of Medicine and Pharmacy, Department of Cellular and Molecular Biology and Histology, Bucharest, Romania. 2. "C.I.Parhon" National Institute of Endocrinology, Bucharest, Romania. 3. Monza Hospital - Onco Team, Diagnostic, Bucharest, Romania. 4. University of Medicine and Pharmacy Cluj-Napoca, Department of Endocrinology, Cluj-Napoca, Romania.
Abstract
BACKGROUND: Ovarian Leydig cell tumour is a very rare steroid hormones producing mass, causing clinical and biochemical hyperandrogenism. Even if the level of evidence is based on case studies, many authors (but not all) agree that raised androgens increase the cardio-metabolic risk thus early diagnosis and treatment are necessary On the other hand, the endocrine features pointing an ovarian tumour source of testosterone do not indicate the specific histological finding which needs a post-operative conformation. CASE PRESENTATION: We report a case of a 60-year-old woman with a 4-year history of progressive virilisation in association with hypertension, high number of red blood cells, impaired glucose tolerance and dyslipidemia. Total testosterone was 20 times above normal with suppressed gonadotropins, inadequate for menopause. Trans-vaginal ultrasound and pelvic and abdominal computerized axial tomography imaging revealed a right ovarian solid nodule, and no evidence of alteration in the adrenal glands. Total hysterectomy and bilateral salpingo-oophorectomy were performed. Histopathology and immunohistochemistry confirmed the diagnosis of Leydig cell tumour. After surgery, androgen levels returned to normal and the doses of anti-hypertensive drugs were reduced. CONCLUSIONS: The hyperandrogenic state with elevated plasma testosterone and progressive signs of virilization raises suspicion of an ovarian androgen-secreting tumor. For a postmenopausal patient with hyperandrogenism the diagnosis of Leydig cell tumour should be considered. However, the exact diagnosis is provided by post-operative histological exam. Prolonged exposure to hyperandrogenism may generate cardiovascular abnormalities and metabolic syndrome which after tumor excision and removal of the source of androgen hormones are expected to significantly improve.
BACKGROUND: Ovarian Leydig cell tumour is a very rare steroid hormones producing mass, causing clinical and biochemical hyperandrogenism. Even if the level of evidence is based on case studies, many authors (but not all) agree that raised androgens increase the cardio-metabolic risk thus early diagnosis and treatment are necessary On the other hand, the endocrine features pointing an ovarian tumour source of testosterone do not indicate the specific histological finding which needs a post-operative conformation. CASE PRESENTATION: We report a case of a 60-year-old woman with a 4-year history of progressive virilisation in association with hypertension, high number of red blood cells, impaired glucose tolerance and dyslipidemia. Total testosterone was 20 times above normal with suppressed gonadotropins, inadequate for menopause. Trans-vaginal ultrasound and pelvic and abdominal computerized axial tomography imaging revealed a right ovarian solid nodule, and no evidence of alteration in the adrenal glands. Total hysterectomy and bilateral salpingo-oophorectomy were performed. Histopathology and immunohistochemistry confirmed the diagnosis of Leydig cell tumour. After surgery, androgen levels returned to normal and the doses of anti-hypertensive drugs were reduced. CONCLUSIONS: The hyperandrogenic state with elevated plasma testosterone and progressive signs of virilization raises suspicion of an ovarian androgen-secreting tumor. For a postmenopausal patient with hyperandrogenism the diagnosis of Leydig cell tumour should be considered. However, the exact diagnosis is provided by post-operative histological exam. Prolonged exposure to hyperandrogenism may generate cardiovascular abnormalities and metabolic syndrome which after tumor excision and removal of the source of androgen hormones are expected to significantly improve.
Authors: André M Faria; Ricardo V Perez; José A M Marcondes; Daniel S Freire; Roberto Blasbalg; José Soares; Kleber Simões; Sylvia A Y Hayashida; Maria A A Pereira Journal: Nat Rev Endocrinol Date: 2011-02-15 Impact factor: 43.330
Authors: Esther S Vollaard; André P van Beek; Frederik A J Verburg; Annemieke Roos; Jolande A Land Journal: J Clin Endocrinol Metab Date: 2011-02-09 Impact factor: 5.958
Authors: Catalina Poiana; Ioana Virtej; Mara Carsote; Gabriel Banceanu; Maria Sajin; Bogdan Stanescu; Dumitru Ioachim; Dan Hortopan; Mihail Coculescu Journal: Gynecol Endocrinol Date: 2010-08 Impact factor: 2.260
Authors: Sherita Hill Golden; Jingzhong Ding; Moyses Szklo; Maria Ines Schmidt; Bruce B Duncan; Adrian Dobs Journal: Am J Epidemiol Date: 2004-09-15 Impact factor: 4.897
Authors: Nina Ionovici; Mara Carsote; Dana Cristina Terzea; Anca Mihaela Predescu; Anne Marie Rauten; Mihaela Popescu Journal: Rom J Morphol Embryol Date: 2020 Apr-Jun Impact factor: 1.033